Key answer coming to us mid August!Germany's medical growth is a leading indicator and under 'normal' circumstances should be shown in the bottom line by MPL since they have the same capabilities as other players enjoying the growth in Germany. MPL has the same licenses, certifications, facilities, processes, etc. as other players enjoying that growth. It's all apples to apples.
What will it tell you if MPL's financial performance announced around mid August is not showing the same trend as the leading indicator is?
It should tell you that the pharma companies in Germany are not sharing that pie with MPL in the same way because the CEO lacks credibility and his involvement with the opioid crisis.
Then it's time for a new CEO that is 'trusted' amongst the peers of the pharma industry in Germany and other countries as well.
Put simply then if that happens, he's an idiot and we don't want to work with MPL as long as he's CEO.